Portfolio company
Verve Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops gene-editing medicines to treat patients with cardiovascular diseases and genetic disorders like familial hypercholesterolemia.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Lexeo Therapeutics
This clinical-stage company develops gene therapies for patients with genetically defined cardiovascular diseases and Alzheimer's disease.
EDITAS Medicine
The company develops CRISPR-based genome editing medicines to treat patients with serious genetic diseases, including blood disorders and inherited eye conditions.
Alia Therapeutics
The company develops gene editing medicines for patients with genetic diseases.
Arbor Biotechnologies
This company develops programmable gene-editing tools and genetic medicines to treat patients with liver and central nervous system diseases.
NewAmsterdam Pharma
The company develops oral therapies to lower cholesterol in patients with cardiovascular disease whose symptoms are inadequately managed by standard statin treatments.
Tenaya
This biotechnology company develops gene therapies and precision medicines for patients suffering from heart disease and rare genetic cardiac conditions.
Phlox Therapeutics
This company develops RNA-based gene therapies to treat patients with rare genetic heart diseases, including cardiomyopathies and laminopathies.
Rocket Pharma
This company develops gene therapies for patients with rare and devastating genetic cardiovascular and haematological diseases.